Prime Medicine, Inc.

PRME
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001894562

Price chart

Open-market purchases and sales by PRME insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Aug 5, 20254:07 PM ETAug 1, 2025Alphabet Inc. and 3 others10% OwnerPPurchaseCommon Stock+1.5M$3.30+$4.95M3.26M+85.1%SEC
Aug 1, 20257:19 PM ETAug 1, 2025ARCH Venture Fund XII, L.P. and 2 others10% OwnerPPurchaseCommon Stock+3.03M$3.30+$10M6.23M+94.7%SEC
Aug 1, 20257:18 PM ETAug 1, 2025CRANDELL KEITH and 7 others10% OwnerPPurchaseCommon Stock+3.03M$3.30+$10M6.23M+94.7%SEC
Aug 1, 2025Aug 1, 2025NELSEN ROBERTDirector, 10% OwnerPPurchaseCommon Stock+3.03M$3.30+$10M6.23M+94.7%SEC
Jul 1, 2025Jun 30, 2025Liu David R.10% OwnerPPurchaseCommon Stock+21K$2.52+$52.92K20.24M+0.1%SEC10b5-1

The largest institutional positions in PRME at the end of Q2 2026.

Institutions holding PRME in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Alphabet Inc.16,562,498$61.12M0.06%00.0%Unchanged
BlackRock, Inc.9,602,041$35.43M0.00%+1,100,333+12.9%Added
ARK Investment Management LLCSuperinvestorARK Invest8,348,746$30.81M0.20%+2,101,919+33.6%Added
STATE STREET CORP7,576,460$27.96M0.00%+1,231,335+19.4%Added
T. Rowe Price Investment Management, Inc.5,237,332$19.33M0.01%−244,561−4.5%Reduced